MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/gastro/goaa042

Медицинская библиотека · Gastroenterology report · 2020

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma.

Hiraoka Atsushi, Kumada Takashi, Tada Toshifumi, Ogawa Chikara, Tani Joji, Fukunishi Shinya, Atsukawa Masanori, Hirooka Masashi, Tsuji Kunihiko, Ishikawa Toru, Takaguchi Koichi, Kariyama Kazuya, Itobayashi Ei, Tajiri Kazuto, Shimada Noritomo, Shibata Hiroshi, Ochi Hironori, Kawata Kazuhito, Toyoda Hidenori, Ohama Hideko, Nouso Kazuhiro, Tsutsui Akemi, Nagano Takuya, Itokawa Norio, Hayama Korenobu, Arai Taeang, Imai Michitaka, Koizumi Yohei, Nakamura Shinichiro, Michitaka Kojiro, Hiasa Yoichi, Kudo Masatoshi, Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular-carcinoma experts from 48 clinics in Japan)

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Lenvatinib is used for unresectable hepatocellular carcinoma (u-HCC) as first-line, as well as second- and third-line therapy in Japan. We evaluated the therapeutic efficacy of newly developed ramucirumab when given after lenvatinib for post-progression treatment.

METHODS

Of 385 patients with u-HCC and treated with lenvatinib at 16 different institutions in Japan between May 2018 and January 2020, 28 who received ramucirumab as the next treatment were enrolled and therapeutic responses were evaluated in a retrospective manner.

RESULTS

The median age of the 28 patients given ramucirumab was 70 years and the median albumin-bilirubin score was -2.19. Of the 28 patients, 23 were male, 21 were classified as Child-Pugh A and 7 as Child-Pugh B, and 25 were Barcelona Clinic Liver Cancer Stage C. Ramucirumab was given as second-line therapy in 14, third-line in 9, and fourth-line in 5. Therapeutic response was obtained in only 26 patients; the objective response rate was 3.8% (1/26) and the disease-control rate was 42.3% (11/26), with a median period to progression of 2.0 months. The reasons for discontinuation of ramucirumab were progression of disease in 16 and Grade 3 adverse events (gastrointestinal bleeding, ascites) in 2.

CONCLUSIONS

The anticipated therapeutic efficacy of ramucirumab for post-progression treatment following lenvatinib was not seen in our early experience.

Для цитирования: Hiraoka Atsushi, Kumada Takashi, Tada Toshifumi, Ogawa Chikara, Tani Joji, Fukunishi Shinya, Atsukawa Masanori, Hirooka Masashi, Tsuji Kunihiko, Ishikawa Toru, Takaguchi Koichi, Kariyama Kazuya, Itobayashi Ei, Tajiri Kazuto, Shimada Noritomo, Shibata Hiroshi, Ochi Hironori, Kawata Kazuhito, Toyoda Hidenori, Ohama Hideko, Nouso Kazuhiro, Tsutsui Akemi, Nagano Takuya, Itokawa Norio, Hayama Korenobu, Arai Taeang, Imai Michitaka, Koizumi Yohei, Nakamura Shinichiro, Michitaka Kojiro, Hiasa Yoichi, Kudo Masatoshi, Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular-carcinoma experts from 48 clinics in Japan). Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma.. Gastroenterology report. 2020. DOI: 10.1093/gastro/goaa042.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.